Floatz logo

TENIFATECAN

Pelvic Neoplasms

Achieve Life SciencesSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Pelvic Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Eli Lilly and Company
Phase 3BB
Inno-206
Eli Lilly and Company
Phase 3BB
Optison
St. Jude Children's Research Hospital
Phase 1CC

Same molecule, other indications

TENIFATECAN is also rated in:

pancreatic neoplasmDormant
CC
Indicative ·
44 / 100
View asset →
colorectal neoplasmDormant
CC
Indicative ·
42 / 100
View asset →
lung neoplasmDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →